bpc-157 intestinal permeability tight junctions study as Targets and Effectors of Mucosal Immune Homeostasis BPC-157 & The Gut-Brain Axis:
Description
A Phase 2 study published in the New England Journal of Medicine in 2023 (Jastreboff et al.) reported substantial weight loss in participants with obesity
Research Disclaimer
Ozempic (semaglutide) is licensed for type 2 diabetes, while Mounjaro (tirzepatide) is approved for both diabetes and weight loss
We track pain, function, and imaging at regular follow-ups
Wimmer, S
